Results: 4

1.
Figure 4

Figure 4. From: Sustained Response and Prevention of Damage Progression in Patients With Neonatal-Onset Multisystem Inflammatory Disease Treated With Anakinra.

Ophthalmology outcomes in patients with neonatal-onset multisystem inflammatory disease treated with anakinra. A, Significant decreases in conjunctivitis and papilledema scores throughout the study. Bars show the mean ± SEM. ** = P < 0.001 versus baseline. B, Significant correlation of low optic nerve thickness, measured by optical coherence tomography, with visual field loss. A near linear correlation was observed for optic nerve thickness of less than ~80μ.

Cailin H. Sibley, et al. Arthritis Rheum. 2012 July;64(7):2375-2386.
2.
Figure 1

Figure 1. From: Sustained Response and Prevention of Damage Progression in Patients With Neonatal-Onset Multisystem Inflammatory Disease Treated With Anakinra.

Systemic manifestations in patients with neonatal-onset multisystem inflammatory disease treated with anakinra. A, Patient diary score, Childhood Health Assessment Questionnaire (C-HAQ) score, parent’s/patient’s global score of overall disease activity, and parent’s/patient’s pain ratings at baseline and after 1, 2, 3, and 5 years of anakinra treatment. B, C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), and serum amyloid A (SAA) level at baseline and after 1, 2, 3, and 5 years of anakinra treatment. Bars show the mean ± SEM. * = P < 0.05; ** = P < 0.001, versus baseline.

Cailin H. Sibley, et al. Arthritis Rheum. 2012 July;64(7):2375-2386.
3.
Figure 2

Figure 2. From: Sustained Response and Prevention of Damage Progression in Patients With Neonatal-Onset Multisystem Inflammatory Disease Treated With Anakinra.

Central nervous system outcomes in patients with neonatal-onset multisystem inflammatory disease treated with anakinra. Lumbar punctures were obtained in 24 of 26 patients at baseline, 24 of 26 patients at 36 months, and 18 of 20 patients at 60 months. Two patients were unable to undergo a lumbar puncture (1 due to spinal lipomatosis and 1 due to technical difficulties). A, Cerebrospinal fluid (CSF) leukocyte (white blood cell [WBC]) count, albumin level, and opening pressure at baseline and after 1, 2, 3, and 5 years of anakinra treatment. Decreases were seen at all time points. Bars show the mean ± SEM. * = P < 0.05; ** = P < 0.001, versus baseline. B, Example of leptomeningeal enhancement seen on the gadolinium-enhanced magnetic resonance image (MRI) obtained at baseline and no longer detected on MRIs obtained at the 3-year and 5-year followup examinations.

Cailin H. Sibley, et al. Arthritis Rheum. 2012 July;64(7):2375-2386.
4.
Figure 3

Figure 3. From: Sustained Response and Prevention of Damage Progression in Patients With Neonatal-Onset Multisystem Inflammatory Disease Treated With Anakinra.

Audiology outcomes in patients with neonatal-onset multisystem inflammatory disease treated with anakinra. A, Comparison of mean bone 4-frequency pure-tone averages (4F-PTAs) (at 0.5k Hz, 1k Hz, 2k Hz, and 4k Hz) at baseline (x-axis) and at the 3-year and 5-year followup examinations (y-axis). The broken line indicates the estimated mean 4F-PTA. Red circles indicate ears with worsening of hearing with a mean change in 4F-PTA of ≥10 dB, and purple circles indicate ears with worsening of hearing with a mean change in 4F-PTA between 5 dB and 10 dB. Green circles indicate hearing in 4 patients (8 ears) who were younger than 20 months of age at enrollment. In these 4 patients, hearing was first assessable by 4F-PTA between 2.5 and 3 years of age, which was used as the baseline, and the last hearing assessment was conducted at 60 months for 3 patients and at 48 months for 1 patient. Upper case letters represent individual patients; r and l indicate the right and left ears, respectively. B, Cochlear enhancement pre– and post–gadolinium contrast on fluid-attenuated inversion recovery magnetic resonance imaging. Arrows indicate the cochlea; arrowheads indicate the vestibule. The enhancement seen on the postcontrast images at baseline had subsided on the images obtained after 3 years of treatment. C, Significantly higher cochlear enhancement scores in ears with hearing loss progression compared to those without hearing loss progression. Bars show the mean ± SEM. * = P < 0.05 versus ears without hearing loss progression.

Cailin H. Sibley, et al. Arthritis Rheum. 2012 July;64(7):2375-2386.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk